{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:07:58Z","timestamp":1755223678774,"version":"3.43.0"},"reference-count":58,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15156","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:39:01Z","timestamp":1750750741000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ning","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"key20250812093526_b1-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"key20250812093526_b2-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"key20250812093526_b3-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"key20250812093526_b4-ol-30-3-15156","first-page":"e21077","article-title":"The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review","volume":"14","author":"Arzoun","year":"2022","journal-title":"Cureus"},{"key":"key20250812093526_b5-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e0202429","DOI":"10.1371\/journal.pone.0202429","article-title":"Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes","volume":"13","author":"Tsuchiya","year":"2018","journal-title":"PLoS One"},{"key":"key20250812093526_b6-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"key20250812093526_b7-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"15","DOI":"10.38094\/jlbsr40172","article-title":"A short review about chronic myeloid leukemia","volume":"4","author":"Al-Bayati","year":"2023","journal-title":"J Life Bio Sci Res"},{"key":"key20250812093526_b8-ol-30-3-15156","first-page":"1182","article-title":"Integrated genomic analysis identifies ANKRD36 gene as a novel and common biomarker of disease progression in chronic myeloid leukemia","volume":"10","author":"Iqbal","year":"2021","journal-title":"Biology (Basel)"},{"key":"key20250812093526_b9-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13104-024-06772-1","article-title":"Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: A Malaysian cohort study","volume":"17","author":"Seman","year":"2024","journal-title":"BMC Res Notes"},{"key":"key20250812093526_b10-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.2147\/OTT.S177019","article-title":"A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"11","author":"Vinhas","year":"2018","journal-title":"OncoTargets Ther"},{"key":"key20250812093526_b11-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e0207170","DOI":"10.1371\/journal.pone.0207170","article-title":"A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib","volume":"14","author":"Kitamura","year":"2019","journal-title":"PLoS One"},{"key":"key20250812093526_b12-ol-30-3-15156","first-page":"40","article-title":"Molecular Biology for BCR-ABL1 quantification for chronic myeloid leukemia monitorization and evaluation","volume":"2","author":"Marin","year":"2021","journal-title":"Arch Cancer Biol Ther"},{"key":"key20250812093526_b13-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"key20250812093526_b14-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"key20250812093526_b15-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"key20250812093526_b16-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4143\/crt.2010.42.1.37","article-title":"Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity","volume":"42","author":"Ahn","year":"2010","journal-title":"Cancer Res Treat"},{"key":"key20250812093526_b17-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/0971-5851.123748","article-title":"Imatinib mesylate resistance and mutations: An Indian experience","volume":"34","author":"Srivastava","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"key20250812093526_b18-ol-30-3-15156","first-page":"412","article-title":"T315I-a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia","volume":"5","author":"Kaleem","year":"2024","journal-title":"Adv Lab Med"},{"key":"key20250812093526_b19-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20250812093526_b20-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3923\/pjbs.2022.175.181","article-title":"Prevalence of BCR-ABL T315I mutation in different chronic myeloid leukemia patients categories","volume":"25","author":"Elsir Khair","year":"2022","journal-title":"Pak J Biol Sci"},{"key":"key20250812093526_b21-ol-30-3-15156","first-page":"110","article-title":"Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia","volume":"37","author":"Wang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"key20250812093526_b22-ol-30-3-15156","first-page":"364","article-title":"Clinical characteristics of chronic myeloid leukemia with T315I mutation and the efficacy of ponatinib","volume":"39","author":"Chen","year":"2019","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"key20250812093526_b23-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"key20250812093526_b24-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"key20250812093526_b25-ol-30-3-15156","first-page":"162","article-title":"Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy","volume":"74","author":"Ortiz","year":"2017","journal-title":"Rev Fac Cien Med Univ Nac Cordoba"},{"key":"key20250812093526_b26-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2050-7771-2-6","article-title":"Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib","volume":"2","author":"Takahashi","year":"2014","journal-title":"Biomark Res"},{"key":"key20250812093526_b27-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000524706","article-title":"Differences in variants in the structural domain of BCR-ABL1 kinase between Chinese Han and Minority patients with chronic myeloid leukemia by sanger sequencing and next-generation sequencing","volume":"162","author":"Abulaiti","year":"2022","journal-title":"Cytogenet Genome Res"},{"key":"key20250812093526_b28-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.leukres.2008.12.017","article-title":"Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations","volume":"33","author":"Kim","year":"2009","journal-title":"Leuk Res"},{"key":"key20250812093526_b29-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"862504","DOI":"10.3389\/fphar.2022.862504","article-title":"Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20250812093526_b30-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41375-024-02411-7","article-title":"Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy","volume":"38","author":"Innes","year":"2024","journal-title":"Leukemia"},{"key":"key20250812093526_b31-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"key20250812093526_b32-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250812093526_b33-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: Results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"key20250812093526_b34-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gene.2005.10.033","article-title":"Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family","volume":"369","author":"Fisher","year":"2006","journal-title":"Gene"},{"key":"key20250812093526_b35-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"key20250812093526_b36-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"key":"key20250812093526_b37-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"key20250812093526_b38-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/ajco.12588","article-title":"ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia","volume":"13","author":"Valikhani","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20250812093526_b39-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"key":"key20250812093526_b40-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","article-title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations","volume":"116","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"key20250812093526_b41-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"key":"key20250812093526_b42-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/JBM.S78826","article-title":"Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms","volume":"6","author":"Yonal-Hindilerden","year":"2015","journal-title":"J Blood Med"},{"key":"key20250812093526_b43-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20250812093526_b44-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3324\/haematol.2019.235150","article-title":"The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia","volume":"106","author":"D'Altri","year":"2021","journal-title":"Haematologica"},{"key":"key20250812093526_b45-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20250812093526_b46-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol Detect Quantif"},{"key":"key20250812093526_b47-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.12194","article-title":"Next-generation sequencing-feasibility and practicality in haematology","volume":"160","author":"Kohlmann","year":"2013","journal-title":"Br J Haematol"},{"key":"key20250812093526_b48-ol-30-3-15156","first-page":"100184","article-title":"T315I-mutated myeloid sarcoma","volume":"12","author":"Zhang","year":"2019","journal-title":"Leuk Res Rep"},{"key":"key20250812093526_b49-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1369246","DOI":"10.3389\/fonc.2024.1369246","article-title":"Exploring treatment decision-making in chronic myeloid leukemia in chronic phase","volume":"14","author":"Andorsky","year":"2024","journal-title":"Front Oncol"},{"key":"key20250812093526_b50-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e38985","DOI":"10.1097\/MD.0000000000038985","article-title":"Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"key20250812093526_b51-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023-common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20250812093526_b52-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.3390\/cancers15164161","article-title":"A multicenter retrospective chart review study of treatment and disease patterns and clinical outcomes of patients with chronic-phase chronic myeloid leukemia in third-line treatment or with T315I mutation","volume":"15","author":"Nicolini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20250812093526_b53-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14740\/jmc4287","article-title":"Combination therapy with asciminib and ponatinib as a bridge to brexucabtagene autoleucel and maintenance in a patient with relapsed refractory philadelphia positive B-cell acute lymphoblastic leukemia","volume":"15","author":"Amin Muhammad","year":"2024","journal-title":"J Med Cases"},{"key":"key20250812093526_b54-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41423-023-01112-y","article-title":"The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation","volume":"21","author":"Luo","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"key20250812093526_b55-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdv110","article-title":"A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia","volume":"26","author":"Korfi","year":"2015","journal-title":"Ann Oncol"},{"key":"key20250812093526_b56-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"e70317","DOI":"10.1002\/cam4.70317","article-title":"New ABL1 kinase domain mutations in BCR::ABL1-positive acute lymphoblastic leukemia","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"key":"key20250812093526_b57-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: The first-in-class allosteric inhibitor of BCR::ABL1 kinase","author":"Choi","year":"2023","journal-title":"Blood Res 58(S1)"},{"key":"key20250812093526_b58-ol-30-3-15156","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7754\/Clin.Lab.2014.140818","article-title":"E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib","volume":"61","author":"Li","year":"2015","journal-title":"Clin Lab"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T06:35:35Z","timestamp":1754980535000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15156","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}